PepGen (PEPG) Liabilities and Shareholders Equity (2021 - 2026)
PepGen (PEPG) posted Liabilities and Shareholders Equity of $156.3 million for Q1 2026, down 10.13% sequentially from $173.9 million in Q4 2025, and up 22.69% YoY from $127.4 million in Q1 2025.
Analysis
PepGen (PEPG) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
PepGen has reported Liabilities and Shareholders Equity for 6 years, with the latest figure at $156.3 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 22.69% year-over-year to $156.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $622.5 million (down 3.04% YoY) and the FY2025 annual result came in at $173.9 million, up 15.26% from the prior year.
- Liabilities and Shareholders Equity slipped to $156.3 million in Q1 2026 per PEPG's latest filing, from $173.9 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $230.8 million in Q2 2022 and troughed at $102.2 million in Q2 2025.
- A 5-year average of $173.6 million and a median of $173.9 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity jumped 52.44% in 2023, then tumbled 47.16% in 2025.
- Over 5 years, Liabilities and Shareholders Equity stood at $217.4 million in 2022, then slumped by 34.21% to $143.1 million in 2023, then gained by 5.47% to $150.9 million in 2024, then advanced by 15.26% to $173.9 million in 2025, then decreased by 10.13% to $156.3 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $156.3 million, $173.9 million, and $190.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 10.96 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.32 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9.18 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.82 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.10 Bn |
| 10 | PepGen | 217.99 Mn | 217.99 Mn | - | 141.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 141.40 Mn |
| Mar 31, 2026 | 156.30 Mn |
| Dec 31, 2025 | 173.91 Mn |
| Sep 30, 2025 | 190.06 Mn |
| Jun 30, 2025 | 102.24 Mn |
| Mar 31, 2025 | 127.39 Mn |
| Dec 31, 2024 | 150.88 Mn |
| Sep 30, 2024 | 170.23 Mn |
| Jun 30, 2024 | 193.51 Mn |
| Mar 31, 2024 | 207.00 Mn |
| Dec 31, 2023 | 143.05 Mn |
| Sep 30, 2023 | 164.27 Mn |
| Jun 30, 2023 | 182.09 Mn |
| Mar 31, 2023 | 201.04 Mn |
| Dec 31, 2022 | 217.44 Mn |
| Sep 30, 2022 | 208.46 Mn |
| Jun 30, 2022 | 230.80 Mn |
| Mar 31, 2022 | 131.88 Mn |
| Dec 31, 2021 | 143.64 Mn |